Modern Texture Safety Profile

The implant surface landscape has changed substantially since the 2019 BIOCELL macrotextured recall. The 2026 picture differs significantly from the 2018 textured-dominant era.

The 2026 surface landscape

Surface	Pore size	BIA-ALCL risk	Capsular contracture	Status
Smooth	~0 µm	Essentially undetectable	~3-6% over 10 years (modern shells)	Standard for round implants — modern resurgence
Microtextured (Siltex)	~50-100 µm	~1 in 30,000-50,000	~2-5% over 10 years	Standard for anatomical implants
Microtextured (SilkSurface)	~30-50 µm	Very low	~2-5% over 10 years	Premium — boundary smooth/microtextured
Macrotextured (BIOCELL)	~200-700 µm	~1 in 2,000-3,000	~1-3% over 10 years	RECALLED 2019
Polyurethane-coated	Foam coating	Very low	~1-2% over 10 years	European specialty (Polytech)

Modern practice patterns

Approximate distribution of new implant placements in 2026 by surface:

Smooth surface: ~60-70% of new placements (modern resurgence)
Microtextured: ~25-30% (primarily anatomical implants)
Polyurethane-coated: ~3-5% (European specialty + revision)
Macrotextured: Under 1% (mostly withdrawn)

This represents a meaningful shift from the 2018 textured-dominant era when macrotextured (especially BIOCELL) accounted for substantial share of placements.

The shell technology story

Modern smooth-surface implants benefit from substantial shell technology improvements:

Multi-layer shell construction — improved durability and rupture resistance.
Refined manufacturing — reduced shell defects and improved consistency.
Modern cohesive gel — gel cohesiveness reduces consequences if rupture occurs.
Specific antimicrobial considerations — surface preparation to reduce biofilm formation.

The combination has reduced modern smooth implant capsular contracture rates substantially compared to 1990s-2000s smooth implants. The historical "smooth implants have higher contracture" pattern has narrowed meaningfully.

The shifted decision logic

2010-2018 era logic

Texture preferred for lower capsular contracture rates.
BIA-ALCL not yet recognized as significant concern.
Macrotextured (BIOCELL) was dominant choice for many patients.
Smooth surface considered "older" or less sophisticated.

2024-2026 era logic

BIA-ALCL risk hierarchy drives surface choice for round implants.
Modern smooth shells produce comparable contracture rates to textured.
Smooth surface preferred for round implants (lowest BIA-ALCL risk).
Microtextured retained for anatomical implants (rotation prevention).
Polyurethane-coated for specific revision indications.
Macrotextured essentially withdrawn from new placements.

What this means for patients

Considering new implants

Round implants: smooth surface is the modern default (lowest BIA-ALCL risk; comparable contracture to textured).
Anatomical implants: microtextured required (rotation prevention).
BIA-ALCL minimization priority: smooth surface.
Polyurethane-coated: for specific revision indications.

Existing macrotextured implants

Confirm specific brand and texture from operative records.
BIOCELL specifically: highest-risk profile but treatable when caught early.
Monitor for symptoms (late-onset seroma, asymmetry, masses).
Maintain routine surveillance imaging (every 2-3 years).
Prophylactic explant not required for asymptomatic patients but supported for personal preference.

Existing microtextured implants

Lower BIA-ALCL risk than macrotextured.
Standard surveillance for rupture.
No specific BIA-ALCL action needed for most patients.
Monitor for symptoms as standard.

Existing smooth implants

Essentially undetectable BIA-ALCL risk.
Standard surveillance for rupture.
No specific BIA-ALCL concern.

The continuing evolution

The implant surface landscape continues to evolve:

Manufacturer innovation — fine surface technologies (SmoothSilk, etc.) at the boundary smooth/microtextured.
Long-term data — registries continue accumulating multi-decade follow-up.
Patient preference shift — toward lower-risk surfaces for primary placement.
Regulatory environment — continued surveillance and refinement of safety standards.

The 2026 picture represents substantially safer overall surface profile than 2018 — and the trajectory continues toward continued refinement.

Frequently asked questions

Has the texture safety landscape changed since 2019?

Yes — fundamentally. The 2019 BIOCELL recall removed the highest-risk macrotextured surface from the market. Modern practice uses smooth (lowest BIA-ALCL risk) and microtextured (very low risk, used for anatomical implants where rotation prevention is needed). Polyurethane-coated remains a specialty option. The total population-level BIA-ALCL incidence has decreased meaningfully as macrotextured implants are no longer placed and existing BIOCELL implants gradually age out of the population.

Are all microtextured implants equally safe?

Lower BIA-ALCL risk than macrotextured but with subtle variation among microtextured types. Mentor Siltex: well-established with substantial clinical follow-up data; ~1 in 30,000-50,000 lifetime risk. Motiva SilkSurface: finer 3D-imprinted texture (boundary smooth/microtextured); lower BIA-ALCL incidence in current data. Polytech POLYtxt: established European microtextured. Other microtextured surfaces: variable depending on specific texturing process. The clinical category 'microtextured' contains some variation in risk profile.

Is smooth surface really 'no risk' for BIA-ALCL?

Essentially undetectable in current data — but very rare cases have been reported. The current evidence shows smooth surface BIA-ALCL incidence is so low it cannot be reliably quantified — likely under 1 in 1,000,000 if any. For patients prioritising lowest BIA-ALCL risk, smooth surface is the appropriate choice. Some patients with strong family history of lymphoma or other concerns specifically choose smooth for this reason.

What about patients with existing macrotextured implants?

Most macrotextured patients are not BIOCELL — and BIOCELL was the highest-risk specifically. Other macrotextured surfaces (now largely withdrawn) had elevated risk but lower than BIOCELL. Patients with any macrotextured implant should: confirm specific implant brand and texture from operative records, monitor for symptoms (late-onset seroma, asymmetry), maintain routine surveillance imaging. Automatic prophylactic explant not recommended; elective explant for personal reassurance is supported.

Does the texture choice still matter for capsular contracture?

Less than historically thought. Older data suggested textured surfaces had ~2x lower contracture rates. Modern data shows: improved smooth shell technology has narrowed the difference; modern smooth contracture rates ~3-6% vs modern microtextured ~2-5% — meaningful but smaller gap than historical 5-8% smooth vs 1-3% textured. For capsular contracture revision, polyurethane-coated remains lowest-recurrence choice. For primary augmentation, the contracture difference between smooth and microtextured is smaller than the BIA-ALCL difference now favoring smooth.

Modern texture safety profile: 2026 update